1. AR inhibition decreases ER+/AR+ breast cancer growth.
AR inhibition decreases ER+/AR+ breast cancer growth. A, proliferation of MCF7 cells treated with increasing concentrations of enzalutamide (Enza) was monitored by IncuCyte. B, MCF7 cells were grown in soft agar with enzalutamide or tamoxifen and colony size was measured by ImageJ. C, immunoblotting for AR, ER, and Tubulin in MCF7 cells expressing a nontargeting (shNeg) or AR-targeting (shAR15 and shAR17) shRNA constructs (top). Proliferation was monitored by IncuCyte (bottom). D, MCF7 cells were grown in media with CSS for 72 hours then treated with vehicle (Veh), E2, or E2 + enzalutamide or MJC13 and cell number was measured by crystal violet. E, MCF7 cells were grown in media with CSS for 72 hours then treated with Veh, E2, or E2 + enzalutamide for 24 hours followed by cell-cycle analysis. F, MCF7 cells expressing shNeg, shAR15, or shAR17 were cultured in media with CSS for 72 hours then treated with vehicle or E2 and growth was measured by crystal violet. Error bars, SEM. *, P < 0.05; ****, P < by ANOVA with Dunnett multiple comparison test.
Nicholas C. D'Amato et al. Mol Cancer Res 2016;14:
©2016 by American Association for Cancer Research